Skip to main content
Top
Published in: Surgical Endoscopy 8/2014

01-08-2014

Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later

Authors: Mark Noar, Patrick Squires, Emmanuelle Noar, Martin Lee

Published in: Surgical Endoscopy | Issue 8/2014

Login to get access

Abstract

Background

Patients with gastroesophageal reflux disease (GERD) often seek alternative therapy for inadequate symptom control, with over 40 % not responding to medical treatment. We evaluated the long-term safety, efficacy, and durability of response to radiofrequency treatment of the lower esophageal sphincter (Stretta).

Methods

Using an intent-to-treat analysis, we prospectively assessed 217 patients with medically refractory GERD before and after Stretta. There was no concurrent control group in the study. Primary outcome measure was normalization of GERD-health-related quality of life (GERD-HRQL) in 70 % or greater of patients at 10 years. Secondary outcomes were 50 % reduction or elimination of proton pump inhibitors (PPIs) and 60 % or greater improvement in satisfaction at 10 years. Successful treatment was defined as achievement of secondary outcomes in a minimum of 50 % of patients. Complications and effect on existing comorbidities were evaluated. The results of a 10-year study are reported.

Results

The primary outcome was achieved in 72 % of patients (95 % confidence interval 65–79). For secondary outcomes, a 50 % or greater reduction in PPI use occurred in 64 % of patients, (41 % eliminating PPIs entirely), and a 60 % or greater increase in satisfaction occurred in 54 % of patients. Both secondary endpoints were achieved. The most common side effect was short-term chest pain (50 %). Pre-existing Barrett’s metaplasia regressed in 85 % of biopsied patients. No cases of esophageal cancer occurred.

Conclusions

In this single-group evaluation of 217 patients before and after Stretta, GERD-HRQL scores, satisfaction, and PPI use significantly improved and results were immediate and durable at 10 years.
Literature
1.
go back to reference Wiklund I (2004) Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 22:108–114PubMedCrossRef Wiklund I (2004) Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 22:108–114PubMedCrossRef
2.
go back to reference Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–1187PubMedCentralPubMedCrossRef Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, DiBonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ (2012) Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143:1179–1187PubMedCentralPubMedCrossRef
3.
go back to reference Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J (2010) Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil 16:353–362PubMedCentralPubMedCrossRef Miwa H, Kondo T, Oshima T, Fukui H, Tomita T, Watari J (2010) Esophageal sensation and esophageal hypersensitivity—overview from bench to bedside. J Neurogastroenterol Motil 16:353–362PubMedCentralPubMedCrossRef
4.
go back to reference Livstone EM, Sheahan DG, Behar J (1977) Studies of esophageal epithelial cell proliferation in patients with reflux esophagitis. Gastroenterology 73:1315–1319PubMed Livstone EM, Sheahan DG, Behar J (1977) Studies of esophageal epithelial cell proliferation in patients with reflux esophagitis. Gastroenterology 73:1315–1319PubMed
5.
go back to reference Harnett KM, Rieder F, Behar J, Biancani P (2010) Viewpoints on acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil 16:374–388PubMedCentralPubMedCrossRef Harnett KM, Rieder F, Behar J, Biancani P (2010) Viewpoints on acid-induced inflammatory mediators in esophageal mucosa. J Neurogastroenterol Motil 16:374–388PubMedCentralPubMedCrossRef
6.
go back to reference Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ (2009) Gastroesophageal reflux might cause esophagitis through cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137:1776–1784PubMedCrossRef Souza RF, Huo X, Mittal V, Schuler CM, Carmack SW, Zhang HY, Zhang X, Yu C, Hormi-Carver K, Genta RM, Spechler SJ (2009) Gastroesophageal reflux might cause esophagitis through cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology 137:1776–1784PubMedCrossRef
7.
go back to reference Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P (2001) Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357:1338–1339PubMedCrossRef Yiangou Y, Facer P, Dyer NH, Chan CL, Knowles C, Williams NS, Anand P (2001) Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357:1338–1339PubMedCrossRef
8.
go back to reference Veronesi B, Carter JD, Devlin RB, Simon SA, Oortgiesen M (1999) Neuropeptides and capsaicin stimulate the release of inflammatory cytokines in a human bronchial epithelial cell line. Neuropeptides 33:447–456PubMedCrossRef Veronesi B, Carter JD, Devlin RB, Simon SA, Oortgiesen M (1999) Neuropeptides and capsaicin stimulate the release of inflammatory cytokines in a human bronchial epithelial cell line. Neuropeptides 33:447–456PubMedCrossRef
9.
go back to reference Cheng L, Cao W, Behar J, Fiocchi C, Biancani P, Harnett KM (2006) Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther 319:117–126PubMedCrossRef Cheng L, Cao W, Behar J, Fiocchi C, Biancani P, Harnett KM (2006) Acid-induced release of platelet-activating factor by human esophageal mucosa induces inflammatory mediators in circular smooth muscle. J Pharmacol Exp Ther 319:117–126PubMedCrossRef
10.
go back to reference Sampliner RE (1999) A population prevalence of Barrett’s esophagus: finally. Gastroenterology 116:277–285CrossRef Sampliner RE (1999) A population prevalence of Barrett’s esophagus: finally. Gastroenterology 116:277–285CrossRef
11.
go back to reference Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383PubMedCrossRef Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365:1375–1383PubMedCrossRef
12.
go back to reference Kahrilas PJ (2011) The problems with surveillance of Barrett’s esophagus. N Engl J Med 365:1437–1438PubMedCrossRef Kahrilas PJ (2011) The problems with surveillance of Barrett’s esophagus. N Engl J Med 365:1437–1438PubMedCrossRef
13.
go back to reference Metz DC (2004) Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 117(suppl 5A):49S–55SPubMed Metz DC (2004) Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 117(suppl 5A):49S–55SPubMed
14.
go back to reference Chiba N, De Gara CJ, Wilkinson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology 112:1798–1810PubMedCrossRef Chiba N, De Gara CJ, Wilkinson JM et al (1997) Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology 112:1798–1810PubMedCrossRef
15.
go back to reference Ali T, Roberts DN, Tierney WM (2009) Long-term safety concerns with proton pump inhibitors. Am J Med 122(10):896–903PubMedCrossRef Ali T, Roberts DN, Tierney WM (2009) Long-term safety concerns with proton pump inhibitors. Am J Med 122(10):896–903PubMedCrossRef
16.
go back to reference Girgis CM, Sher D, Seibel MJ (2010) Atypical femoral fractures and bisphosphonate use. N Engl J Med 362:1848–1849PubMedCrossRef Girgis CM, Sher D, Seibel MJ (2010) Atypical femoral fractures and bisphosphonate use. N Engl J Med 362:1848–1849PubMedCrossRef
18.
go back to reference Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Adverse risks associated with proton pump inhibitors. Gastroenterol Hepatol 5(10):725–734 Heidelbaugh JJ, Goldberg KL, Inadomi JM (2009) Adverse risks associated with proton pump inhibitors. Gastroenterol Hepatol 5(10):725–734
19.
go back to reference Ghebremariam YT, Lependu P, Lee JC et al (2013) Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128(8):845–853PubMedCrossRef Ghebremariam YT, Lependu P, Lee JC et al (2013) Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation 128(8):845–853PubMedCrossRef
20.
go back to reference Dean BB, Aguilar D, Crawley JA, Dubois RW (2003) Impact of gastroesophageal reflux disease on worker productivity in an employed U.S. population. Gastroenterology 124(4 Suppl 1):A505CrossRef Dean BB, Aguilar D, Crawley JA, Dubois RW (2003) Impact of gastroesophageal reflux disease on worker productivity in an employed U.S. population. Gastroenterology 124(4 Suppl 1):A505CrossRef
21.
go back to reference Crawley JA, Hamelin B, Gallagher E (2000) How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medication? Gastroenterology 118(4 Pt 1):A210CrossRef Crawley JA, Hamelin B, Gallagher E (2000) How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medication? Gastroenterology 118(4 Pt 1):A210CrossRef
22.
go back to reference Spechler SJ, Lee E, Ahnen D et al (2001) Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285:2331–2338PubMedCrossRef Spechler SJ, Lee E, Ahnen D et al (2001) Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 285:2331–2338PubMedCrossRef
23.
go back to reference Mahmood Z, McMahon BP, Arfin Q, Byrne PJ, Reynolds JV, Murphy EM, Weir DG (2003) Endocinch therapy for gastrooesophageal reflux disease: a 1 year prospective follow up. Gut 52:34–39PubMedCentralPubMedCrossRef Mahmood Z, McMahon BP, Arfin Q, Byrne PJ, Reynolds JV, Murphy EM, Weir DG (2003) Endocinch therapy for gastrooesophageal reflux disease: a 1 year prospective follow up. Gut 52:34–39PubMedCentralPubMedCrossRef
24.
go back to reference Deviere J, Costamagna G, Neuhaus H, Voderholzer W, Louis H, Tringali A, Marchese M, Fiedler T, Darb-Esfahani P, Schumacher B (2005) Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multi-center trial. Gastroenterology 128:532–540PubMedCrossRef Deviere J, Costamagna G, Neuhaus H, Voderholzer W, Louis H, Tringali A, Marchese M, Fiedler T, Darb-Esfahani P, Schumacher B (2005) Nonresorbable copolymer implantation for gastroesophageal reflux disease: a randomized sham-controlled multi-center trial. Gastroenterology 128:532–540PubMedCrossRef
25.
go back to reference Fockens P, Bruno MJ, Gabbrielli A, Odegaard S, Hatlebakk J, Allescher HD, Rosch T, Rhodes M, Bastid C, Rey J, Boyer J, Muehldorffer S, van den Hombergh U, Costamagna G (2004) Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: multicenter study of the gatekeeper reflux repair system. Endoscopy 36:682–689PubMedCrossRef Fockens P, Bruno MJ, Gabbrielli A, Odegaard S, Hatlebakk J, Allescher HD, Rosch T, Rhodes M, Bastid C, Rey J, Boyer J, Muehldorffer S, van den Hombergh U, Costamagna G (2004) Endoscopic augmentation of the lower esophageal sphincter for the treatment of gastroesophageal reflux disease: multicenter study of the gatekeeper reflux repair system. Endoscopy 36:682–689PubMedCrossRef
26.
go back to reference Donahue PE, Carvalho P, Yoshida J, Miidla I, Shen YJ, Bombeck CT, Nyhus LM (1989) Endoscopic sclerosis of the cardia affects gastroesophageal reflux. Surg Endosc 3(1):11–12PubMedCrossRef Donahue PE, Carvalho P, Yoshida J, Miidla I, Shen YJ, Bombeck CT, Nyhus LM (1989) Endoscopic sclerosis of the cardia affects gastroesophageal reflux. Surg Endosc 3(1):11–12PubMedCrossRef
27.
go back to reference O’Connor KW, Lehman GA (1988) Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux: a pilot study of 10 medically intractable patients. Gastrointest Endosc 34:106–112PubMedCrossRef O’Connor KW, Lehman GA (1988) Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux: a pilot study of 10 medically intractable patients. Gastrointest Endosc 34:106–112PubMedCrossRef
28.
go back to reference Triadafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH (2002) The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc 55(2):149–156PubMedCrossRef Triadafilopoulos G, DiBaise JK, Nostrant TT, Stollman NH (2002) The Stretta procedure for the treatment of GERD: 6 and 12 month follow-up of the US open label trial. Gastrointest Endosc 55(2):149–156PubMedCrossRef
29.
go back to reference Cadiere GB, Buset M, Muls V et al (2008) Antireflux trabsoral incisionless fundoplication using Esophyx: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688PubMedCentralPubMedCrossRef Cadiere GB, Buset M, Muls V et al (2008) Antireflux trabsoral incisionless fundoplication using Esophyx: 12-month results of a prospective multicenter study. World J Surg 32:1676–1688PubMedCentralPubMedCrossRef
30.
go back to reference Bonavina L, DeMeester TR, Ganz RA (2012) LINX Reflux Management System: magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 6:667–674PubMedCrossRef Bonavina L, DeMeester TR, Ganz RA (2012) LINX Reflux Management System: magnetic sphincter augmentation in the treatment of gastroesophageal reflux disease. Expert Rev Gastroenterol Hepatol 6:667–674PubMedCrossRef
31.
go back to reference Rodríguez L, Rodriguez P, Gómez B, Ayala JC, Saba J, Perez-Castilla A, Galvao Neto M, Crowell MD (2012) Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc Surg Endosc 27(4):1083–1092CrossRef Rodríguez L, Rodriguez P, Gómez B, Ayala JC, Saba J, Perez-Castilla A, Galvao Neto M, Crowell MD (2012) Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc Surg Endosc 27(4):1083–1092CrossRef
32.
go back to reference Falk GW, Fennerty MB, Rothstein RI (2006) AGA Institute technical review on the use of endoscopic therapy for gastrooesophageal reflux disease. Gastroenterology 131:1315–1336PubMedCrossRef Falk GW, Fennerty MB, Rothstein RI (2006) AGA Institute technical review on the use of endoscopic therapy for gastrooesophageal reflux disease. Gastroenterology 131:1315–1336PubMedCrossRef
33.
go back to reference Fry LC, Mönkemüller K, Malfertheiner P (2007) Systematic review: endoluminal therapy for gastrooesophageal reflux disease: evidence from clinical trials. Eur J Gastroenterol Hepatol 19:1125–1139PubMedCrossRef Fry LC, Mönkemüller K, Malfertheiner P (2007) Systematic review: endoluminal therapy for gastrooesophageal reflux disease: evidence from clinical trials. Eur J Gastroenterol Hepatol 19:1125–1139PubMedCrossRef
34.
go back to reference Chen D, Barber C, McLoughlin P, Thavaneswaran P, Jamieson GG, Maddern GJ (2009) Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 96:128–136PubMedCrossRef Chen D, Barber C, McLoughlin P, Thavaneswaran P, Jamieson GG, Maddern GJ (2009) Systematic review of endoscopic treatments for gastro-oesophageal reflux disease. Br J Surg 96:128–136PubMedCrossRef
35.
go back to reference Corley DA, Katz P, Wo J, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM (2003) Temperature controlled radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD (the Stretta procedure): a randomized, double-blind, sham controlled, multi-center clinical trial. Gastroenterology 125:668–676PubMedCrossRef Corley DA, Katz P, Wo J, Stefan A, Patti M, Rothstein R, Edmundowicz S, Kline M, Mason R, Wolfe MM (2003) Temperature controlled radiofrequency energy delivery to the gastroesophageal junction for the treatment of GERD (the Stretta procedure): a randomized, double-blind, sham controlled, multi-center clinical trial. Gastroenterology 125:668–676PubMedCrossRef
36.
go back to reference Arts J, Bisschops R, Blondeau K, Farré R, Vos R, Holvoet L, Caenepeel P, Lerut A, Tack J (2012) A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol 107(2):222–230PubMedCrossRef Arts J, Bisschops R, Blondeau K, Farré R, Vos R, Holvoet L, Caenepeel P, Lerut A, Tack J (2012) A double-blind sham-controlled study of the effect of radiofrequency energy on symptoms and distensibility of the gastro-esophageal junction in GERD. Am J Gastroenterol 107(2):222–230PubMedCrossRef
37.
go back to reference Triadafilopoulos G (2004) Changes in GERD symptom scores correlate with improvement in esophageal acid exposure after the Stretta procedure. Surg Endosc 18:1038–1044PubMedCrossRef Triadafilopoulos G (2004) Changes in GERD symptom scores correlate with improvement in esophageal acid exposure after the Stretta procedure. Surg Endosc 18:1038–1044PubMedCrossRef
38.
go back to reference Aziz AM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, Guda MF, Lehman GA (2010) A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc 24(4):818–825PubMedCrossRef Aziz AM, El-Khayat HR, Sadek A, Mattar SG, McNulty G, Kongkam P, Guda MF, Lehman GA (2010) A prospective randomized trial of sham, single-dose Stretta, and double-dose Stretta for the treatment of gastroesophageal reflux disease. Surg Endosc 24(4):818–825PubMedCrossRef
39.
go back to reference Perry KA, Banerjee A, Melvin WS (2012) Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 22(4):283–288PubMedCrossRef Perry KA, Banerjee A, Melvin WS (2012) Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 22(4):283–288PubMedCrossRef
40.
go back to reference Noar MD, Lotfi-Emran S (2007) Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. Gastrointest Endosc 65:367–372PubMedCrossRef Noar MD, Lotfi-Emran S (2007) Sustained improvement in symptoms of GERD and antisecretory drug use: 4-year follow-up of the Stretta procedure. Gastrointest Endosc 65:367–372PubMedCrossRef
41.
go back to reference Velanovich V (1999) Comparison of symptomatic and quality of life outcomes of laparoscopic versus open antireflux surgery. Surgery 126:782–789PubMedCrossRef Velanovich V (1999) Comparison of symptomatic and quality of life outcomes of laparoscopic versus open antireflux surgery. Surgery 126:782–789PubMedCrossRef
42.
go back to reference Velanovich V (1998) Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL), quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg 2:141–145PubMedCrossRef Velanovich V (1998) Comparison of generic (SF-36) vs. disease-specific (GERD-HRQL), quality-of-life scales for gastroesophageal reflux disease. J Gastrointest Surg 2:141–145PubMedCrossRef
43.
go back to reference Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–134PubMedCrossRef Velanovich V (2007) The development of the GERD-HRQL symptom severity instrument. Dis Esophagus 20:130–134PubMedCrossRef
44.
go back to reference Utley DS (2003) The Stretta procedure: device, technique, and pre-clinical study data. Gastrointest Endosc Clin North Am 13:135–145CrossRef Utley DS (2003) The Stretta procedure: device, technique, and pre-clinical study data. Gastrointest Endosc Clin North Am 13:135–145CrossRef
45.
go back to reference Reymunde A, Santiago N (2007) Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. Gastrointest Endosc 65:361–366PubMedCrossRef Reymunde A, Santiago N (2007) Long-term results of radiofrequency energy delivery for the treatment of GERD: sustained improvements in symptoms, quality of life, and drug use at 4-year follow-up. Gastrointest Endosc 65:361–366PubMedCrossRef
46.
go back to reference Dughera L, Navino M, Cassolino P, De Cento M, Cacciotella L, Cisarò F, Chiaverina M (2011) Long-term results of radiofrequency energy delivery for the treatment of GERD: results of a prospective 48-month study. Diagn Ther Endosc 2011:507157PubMedCentralPubMedCrossRef Dughera L, Navino M, Cassolino P, De Cento M, Cacciotella L, Cisarò F, Chiaverina M (2011) Long-term results of radiofrequency energy delivery for the treatment of GERD: results of a prospective 48-month study. Diagn Ther Endosc 2011:507157PubMedCentralPubMedCrossRef
47.
go back to reference Fass R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next? Aliment Pharmacol Ther 22(2):79–94PubMedCrossRef Fass R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease where next? Aliment Pharmacol Ther 22(2):79–94PubMedCrossRef
48.
go back to reference Fass R (2012) Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 10(4):338–345PubMedCrossRef Fass R (2012) Alternative therapeutic approaches to chronic proton pump inhibitor treatment. Clin Gastroenterol Hepatol 10(4):338–345PubMedCrossRef
49.
go back to reference Richards WO, Houston HL, Torquati A, Khaitan L, Holzman MD, Sharp KW (2003) Paradigm shift in the management of gastroesophageal reflux disease. Ann Surg 237(5):638–647PubMedCentralPubMed Richards WO, Houston HL, Torquati A, Khaitan L, Holzman MD, Sharp KW (2003) Paradigm shift in the management of gastroesophageal reflux disease. Ann Surg 237(5):638–647PubMedCentralPubMed
50.
go back to reference Hunter JG, Smith CD, Branum GD, Waring JP, Trus TL, Cornwell M, Galloway K (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg 230:595–606PubMedCentralPubMedCrossRef Hunter JG, Smith CD, Branum GD, Waring JP, Trus TL, Cornwell M, Galloway K (1999) Laparoscopic fundoplication failures: patterns of failure and response to fundoplication revision. Ann Surg 230:595–606PubMedCentralPubMedCrossRef
52.
go back to reference Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, Petrie DJ (1980) Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 65:256–267PubMedCentralPubMedCrossRef Dent J, Dodds WJ, Friedman RH, Sekiguchi T, Hogan WJ, Arndorfer RC, Petrie DJ (1980) Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. J Clin Invest 65:256–267PubMedCentralPubMedCrossRef
53.
go back to reference Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P (2003) Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361:385–391PubMedCrossRef Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, Anand P (2003) Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361:385–391PubMedCrossRef
54.
go back to reference Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P (2004) Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 16:897–902PubMedCrossRef Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, Anand P (2004) Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 16:897–902PubMedCrossRef
55.
go back to reference Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, Panzera F, Behar J, Cicala M (2010) Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 22(746–751):e219 Guarino MP, Cheng L, Ma J, Harnett K, Biancani P, Altomare A, Panzera F, Behar J, Cicala M (2010) Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterol Motil 22(746–751):e219
56.
go back to reference Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM (2004) Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol 287:G1131–G1139PubMedCrossRef Cao W, Cheng L, Behar J, Fiocchi C, Biancani P, Harnett KM (2004) Proinflammatory cytokines alter/reduce esophageal circular muscle contraction in experimental cat esophagitis. Am J Physiol Gastrointest Liver Physiol 287:G1131–G1139PubMedCrossRef
57.
go back to reference Cheng L, Cao W, Fiocchi C, Behar J, Biancani P, Harnett KM (2005) In vitro model of acute esophagitis in the cat. Am J Physiol Gastrointest Liver Physiol 289:G860–G869PubMedCrossRef Cheng L, Cao W, Fiocchi C, Behar J, Biancani P, Harnett KM (2005) In vitro model of acute esophagitis in the cat. Am J Physiol Gastrointest Liver Physiol 289:G860–G869PubMedCrossRef
58.
go back to reference Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ (2002) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50:451–459PubMedCentralPubMedCrossRef Fitzgerald RC, Onwuegbusi BA, Bajaj-Elliott M, Saeed IT, Burnham WR, Farthing MJ (2002) Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50:451–459PubMedCentralPubMedCrossRef
59.
go back to reference Isomoto H, Wang A, Mizuta Y, Akazawa Y, Ohba K, Omagari K, Miyazaki M, Murase K, Hayashi T, Inoue K, Murata I, Kohno S (2003) Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol 98:551–556PubMedCrossRef Isomoto H, Wang A, Mizuta Y, Akazawa Y, Ohba K, Omagari K, Miyazaki M, Murase K, Hayashi T, Inoue K, Murata I, Kohno S (2003) Elevated levels of chemokines in esophageal mucosa of patients with reflux esophagitis. Am J Gastroenterol 98:551–556PubMedCrossRef
60.
go back to reference Yoshida N, Uchiyama K, Kuroda M, Sakuma K, Kokura S, Ichikawa H, Naito Y, Takemura T, Yoshikawa T, Okanoue T (2004) Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 39:816–822PubMedCrossRef Yoshida N, Uchiyama K, Kuroda M, Sakuma K, Kokura S, Ichikawa H, Naito Y, Takemura T, Yoshikawa T, Okanoue T (2004) Interleukin-8 expression in the esophageal mucosa of patients with gastroesophageal reflux disease. Scand J Gastroenterol 39:816–822PubMedCrossRef
61.
go back to reference Wardlaw AJ, Moqbel R, Cromwell O, Kay AB (1986) Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78:1701–1706PubMedCentralPubMedCrossRef Wardlaw AJ, Moqbel R, Cromwell O, Kay AB (1986) Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 78:1701–1706PubMedCentralPubMedCrossRef
62.
go back to reference Tam WC, Schoeman MN, Zhang Q, Dent J, Rigda R, Utley D, Holloway RH (2003) Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 52(4):479–485PubMedCentralPubMedCrossRef Tam WC, Schoeman MN, Zhang Q, Dent J, Rigda R, Utley D, Holloway RH (2003) Delivery of radiofrequency energy to the lower oesophageal sphincter and gastric cardia inhibits transient lower oesophageal sphincter relaxations and gastro-oesophageal reflux in patients with reflux disease. Gut 52(4):479–485PubMedCentralPubMedCrossRef
63.
go back to reference Herman R, Berho M, Murawski M, Nowakowski M, Rys J, Schwarz T, Wojtysiak D, Herman RB, Wexner SD (2013) Non-ablative radiofrequency (RF) application to smooth muscle of internal anal sphincter (IAS): a tissue study. Surg Endosc 27:S305CrossRef Herman R, Berho M, Murawski M, Nowakowski M, Rys J, Schwarz T, Wojtysiak D, Herman RB, Wexner SD (2013) Non-ablative radiofrequency (RF) application to smooth muscle of internal anal sphincter (IAS): a tissue study. Surg Endosc 27:S305CrossRef
64.
go back to reference Go MR, Dundon JM, Karlowicz DJ, Domingo CB, Muscarella P, Melvin WS (2004) Delivery of radiofrequency energy to the lower esophageal sphincter improves symptoms of gastroesophageal reflux. Surgery 136:786–794PubMedCrossRef Go MR, Dundon JM, Karlowicz DJ, Domingo CB, Muscarella P, Melvin WS (2004) Delivery of radiofrequency energy to the lower esophageal sphincter improves symptoms of gastroesophageal reflux. Surgery 136:786–794PubMedCrossRef
65.
go back to reference Arts J, Sifrim D, Rutgeerts P, Lerut A, Janssens J, Tack J (2007) Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 52(9):2170–2177PubMedCrossRef Arts J, Sifrim D, Rutgeerts P, Lerut A, Janssens J, Tack J (2007) Influence of radiofrequency energy delivery at the gastroesophageal junction (the Stretta procedure) on symptoms, acid exposure, and esophageal sensitivity to acid perfusion in gastroesophagal reflux disease. Dig Dis Sci 52(9):2170–2177PubMedCrossRef
66.
go back to reference Utley DS, Kim M, Vierra MA, Triadafilopoulos G (2000) Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc 52(1):81–86PubMedCrossRef Utley DS, Kim M, Vierra MA, Triadafilopoulos G (2000) Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model. Gastrointest Endosc 52(1):81–86PubMedCrossRef
67.
go back to reference Noar MD, Noar E (2008) Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc 22(11):2440–2444PubMedCrossRef Noar MD, Noar E (2008) Gastroparesis associated with gastroesophageal reflux disease and corresponding reflux symptoms may be corrected by radiofrequency ablation of the cardia and esophagogastric junction. Surg Endosc 22(11):2440–2444PubMedCrossRef
68.
go back to reference Noar MD, Xu L, Koch KL (2003) Effect of radiofrequency ablation on gastric dysrhythmias in patients with gastroesophageal reflux disease (GERD) and functional dyspepsia. Gastroenterology 124(4 Suppl 1):A98CrossRef Noar MD, Xu L, Koch KL (2003) Effect of radiofrequency ablation on gastric dysrhythmias in patients with gastroesophageal reflux disease (GERD) and functional dyspepsia. Gastroenterology 124(4 Suppl 1):A98CrossRef
69.
70.
go back to reference Louis H (2013) Endoscopic full-thickness plication for the treatment of GERD: is there a future? Gastrointest Endosc 77(1):15–17PubMedCrossRef Louis H (2013) Endoscopic full-thickness plication for the treatment of GERD: is there a future? Gastrointest Endosc 77(1):15–17PubMedCrossRef
71.
go back to reference Coron E, Sebille V, Cadiot G, Zerbib F, Ducrotte P, Ducrot F, Pouderoux P, Arts J, Le Rhun M, Piche T, Bruley des Varannes S, Galmiche JP (2008) Clinical trial: radiofrequency energy delivery in proton pump inhibitor-dependent gastro–oesophageal reflux disease patients. Aliment Pharmacol Ther 28(9):1147–1158PubMedCrossRef Coron E, Sebille V, Cadiot G, Zerbib F, Ducrotte P, Ducrot F, Pouderoux P, Arts J, Le Rhun M, Piche T, Bruley des Varannes S, Galmiche JP (2008) Clinical trial: radiofrequency energy delivery in proton pump inhibitor-dependent gastro–oesophageal reflux disease patients. Aliment Pharmacol Ther 28(9):1147–1158PubMedCrossRef
Metadata
Title
Long-term maintenance effect of radiofrequency energy delivery for refractory GERD: a decade later
Authors
Mark Noar
Patrick Squires
Emmanuelle Noar
Martin Lee
Publication date
01-08-2014
Publisher
Springer US
Published in
Surgical Endoscopy / Issue 8/2014
Print ISSN: 0930-2794
Electronic ISSN: 1432-2218
DOI
https://doi.org/10.1007/s00464-014-3461-6

Other articles of this Issue 8/2014

Surgical Endoscopy 8/2014 Go to the issue